(Total Views: 453)
Posted On: 09/10/2024 10:13:08 AM
Post# of 148863
It looks like the study will be doing 4 arms, LL 350mg alone and with Resmetirom as well as LL 700mg alone and with Resmetirom.
From the 5/30 CC:
Lastly, I'm pleased to announce that CytoDyn is following up on the results of our prior Nash study, which demonstrated a statistically significant benefit of leronlimab at the 350, milligram dose, though not at the 700 milligram dose level.
In order to clarify the optimal dosing regimen for Nash, or now MASH, and efficiently evaluate the potential for combination therapy, we have contracted with a lab to perform a pre-clinical mouse study, evaluating both 350 and 700, milligram dose levels alone, and in combination with Resmetirom, a drug recently approved by the FDA for the treatment of MASH.
From the 5/30 CC:
Lastly, I'm pleased to announce that CytoDyn is following up on the results of our prior Nash study, which demonstrated a statistically significant benefit of leronlimab at the 350, milligram dose, though not at the 700 milligram dose level.
In order to clarify the optimal dosing regimen for Nash, or now MASH, and efficiently evaluate the potential for combination therapy, we have contracted with a lab to perform a pre-clinical mouse study, evaluating both 350 and 700, milligram dose levels alone, and in combination with Resmetirom, a drug recently approved by the FDA for the treatment of MASH.
(10)
(0)Scroll down for more posts ▼
